No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervixCitation formats

  • External authors:
  • P. Kabuubi
  • J. A. Loncaster
  • S. E. Davidson
  • R. D. Hunter

Standard

No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix. / Kabuubi, P.; Loncaster, J. A.; Davidson, S. E.; Hunter, R. D.; Kobylecki, C.; Stratford, I. J.; West, C. M L.

In: British Journal of Cancer, Vol. 94, No. 1, 16.01.2006, p. 115-120.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Kabuubi, P. ; Loncaster, J. A. ; Davidson, S. E. ; Hunter, R. D. ; Kobylecki, C. ; Stratford, I. J. ; West, C. M L. / No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix. In: British Journal of Cancer. 2006 ; Vol. 94, No. 1. pp. 115-120.

Bibtex

@article{7368bb2bd6414040917092a4093e1974,
title = "No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix",
abstract = "The expression of hypoxia-regulated genes promotes an aggressive tumour phenotype and is associated with an adverse cancer treatment outcome. Thymidine phosphorylase (TP) levels increase under hypoxia, but the protein has not been studied in association with hypoxia in human tumours. An investigation was made, therefore, of the relationship of tumour TP with hypoxia, the expression of other hypoxia-associated markers and clinical outcome. This retrospective study was carried out in patients with locally advanced cervical carcinoma who underwent radiotherapy. Protein expression was evaluated with immunohistochemistry. Hypoxia was measured using microelectrodes and the level of pimonidazole binding. There was no relationship of TP expression with tumour pO2 (r = -0.091, P = 0.59, n = 87) or pimonidazole binding (r = 0.13, P = 0.45, n = 38). There was no relationship between TP and HIF-1α, but there was a weak borderline significant relationship with HIF-2α expression. There were weak but significant correlations of TP with the expression of VEGF, CA IX and Glut-1. In 119 patients, the presence of TP expression predicted for disease-specific (P = 0.032) and metastasis-free (P = 0.050) survival. The results suggest that TP is not a surrogate marker of hypoxia, but is linked to the expression of hypoxia-associated genes and has weak prognostic power. {\textcopyright} 2006 Cancer Research.",
keywords = "Cervix, Hypoxia, Hypoxia-inducible factor, Thymidine phosphorylase",
author = "P. Kabuubi and Loncaster, {J. A.} and Davidson, {S. E.} and Hunter, {R. D.} and C. Kobylecki and Stratford, {I. J.} and West, {C. M L}",
year = "2006",
month = jan,
day = "16",
doi = "10.1038/sj.bjc.6602882",
language = "English",
volume = "94",
pages = "115--120",
journal = "BJC",
issn = "0007-0920",
publisher = "Springer Nature",
number = "1",

}

RIS

TY - JOUR

T1 - No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix

AU - Kabuubi, P.

AU - Loncaster, J. A.

AU - Davidson, S. E.

AU - Hunter, R. D.

AU - Kobylecki, C.

AU - Stratford, I. J.

AU - West, C. M L

PY - 2006/1/16

Y1 - 2006/1/16

N2 - The expression of hypoxia-regulated genes promotes an aggressive tumour phenotype and is associated with an adverse cancer treatment outcome. Thymidine phosphorylase (TP) levels increase under hypoxia, but the protein has not been studied in association with hypoxia in human tumours. An investigation was made, therefore, of the relationship of tumour TP with hypoxia, the expression of other hypoxia-associated markers and clinical outcome. This retrospective study was carried out in patients with locally advanced cervical carcinoma who underwent radiotherapy. Protein expression was evaluated with immunohistochemistry. Hypoxia was measured using microelectrodes and the level of pimonidazole binding. There was no relationship of TP expression with tumour pO2 (r = -0.091, P = 0.59, n = 87) or pimonidazole binding (r = 0.13, P = 0.45, n = 38). There was no relationship between TP and HIF-1α, but there was a weak borderline significant relationship with HIF-2α expression. There were weak but significant correlations of TP with the expression of VEGF, CA IX and Glut-1. In 119 patients, the presence of TP expression predicted for disease-specific (P = 0.032) and metastasis-free (P = 0.050) survival. The results suggest that TP is not a surrogate marker of hypoxia, but is linked to the expression of hypoxia-associated genes and has weak prognostic power. © 2006 Cancer Research.

AB - The expression of hypoxia-regulated genes promotes an aggressive tumour phenotype and is associated with an adverse cancer treatment outcome. Thymidine phosphorylase (TP) levels increase under hypoxia, but the protein has not been studied in association with hypoxia in human tumours. An investigation was made, therefore, of the relationship of tumour TP with hypoxia, the expression of other hypoxia-associated markers and clinical outcome. This retrospective study was carried out in patients with locally advanced cervical carcinoma who underwent radiotherapy. Protein expression was evaluated with immunohistochemistry. Hypoxia was measured using microelectrodes and the level of pimonidazole binding. There was no relationship of TP expression with tumour pO2 (r = -0.091, P = 0.59, n = 87) or pimonidazole binding (r = 0.13, P = 0.45, n = 38). There was no relationship between TP and HIF-1α, but there was a weak borderline significant relationship with HIF-2α expression. There were weak but significant correlations of TP with the expression of VEGF, CA IX and Glut-1. In 119 patients, the presence of TP expression predicted for disease-specific (P = 0.032) and metastasis-free (P = 0.050) survival. The results suggest that TP is not a surrogate marker of hypoxia, but is linked to the expression of hypoxia-associated genes and has weak prognostic power. © 2006 Cancer Research.

KW - Cervix

KW - Hypoxia

KW - Hypoxia-inducible factor

KW - Thymidine phosphorylase

U2 - 10.1038/sj.bjc.6602882

DO - 10.1038/sj.bjc.6602882

M3 - Article

VL - 94

SP - 115

EP - 120

JO - BJC

JF - BJC

SN - 0007-0920

IS - 1

ER -